
Annual report 2021
added 12-23-2023
Amryt Pharma plc EBITDA 2011-2026 | AMYT
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Amryt Pharma plc
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -38.6 M | -46.5 M | -50.5 M | -18 M | -16.7 M | -5.95 M | 33.3 M | -2.93 M | -202 K | -275 K | -281 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33.3 M | -50.5 M | -13.3 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Aligos Therapeutics
ALGS
|
-87.1 M | $ 8.74 | 0.23 % | $ 86.4 M | ||
|
Allakos
ALLK
|
-190 M | - | - | $ 28.6 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 3.62 | -1.09 % | $ 8.71 B | ||
|
Aptinyx
APTX
|
-62.4 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-70 M | - | -13.39 % | $ 1.45 M | ||
|
BioNTech SE
BNTX
|
15.3 B | $ 98.41 | 1.77 % | $ 27.2 B | ||
|
Burford Capital Limited
BUR
|
242 M | $ 4.71 | 4.9 % | $ 760 M | ||
|
Cabaletta Bio
CABA
|
-171 M | $ 3.26 | 1.87 % | $ 328 M | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-9.75 M | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
BeiGene, Ltd.
BGNE
|
589 M | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
-216 M | - | - | $ 546 M | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
172 M | $ 21.38 | 0.09 % | $ 999 M | ||
|
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | ||
|
Clearside Biomedical
CLSD
|
-24.8 M | - | - | $ 25.3 M | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-23.9 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
24.8 M | $ 1.56 | 6.12 % | $ 401 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 3.05 | 4.45 % | $ 5.02 M | ||
|
Aquestive Therapeutics
AQST
|
-70.5 M | $ 4.15 | -0.95 % | $ 444 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-11.5 M | $ 25.09 | 4.02 % | $ 3.19 B | ||
|
Chimerix
CMRX
|
-93 M | - | - | $ 756 M | ||
|
Concert Pharmaceuticals
CNCE
|
-76 M | - | - | $ 401 M | ||
|
AIkido Pharma
AIKI
|
-55.6 M | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
-284 M | $ 33.33 | 2.27 % | $ 2.21 B | ||
|
Autolus Therapeutics plc
AUTL
|
-262 M | $ 1.48 | 0.68 % | $ 394 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Cidara Therapeutics
CDTX
|
-176 M | - | - | $ 1.41 B | ||
|
Evogene Ltd.
EVGN
|
-31 M | $ 0.82 | 0.02 % | $ 27.9 M | ||
|
AVROBIO
AVRO
|
10.8 M | - | 1083.1 % | $ 745 M | ||
|
Forte Biosciences
FBRX
|
-70.6 M | $ 32.42 | 5.95 % | $ 420 M | ||
|
CNS Pharmaceuticals
CNSP
|
-16 M | $ 2.64 | 8.42 % | $ 1.17 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
CTI BioPharma Corp.
CTIC
|
-77.8 M | - | - | $ 1.2 B |